DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute on Drug Abuse; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute on Drug Abuse Special Emphasis Panel Cutting-Edge Basic Research Awards (CEBRA) (R21).

Date: March 20, 2018.

Time: 12:00 p.m. to 6:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852 (Virtual Meeting).

Contact Person: Susan O. McGuire, Ph.D., Scientific Review Officer, Office of Extramural Policy and Review, National Institute on Drug Abuse, NIH, DHHS, 6001 Executive Boulevard, Room 4245, MSC 9550, Bethesda, MD 20892, 301–827–5840, mcguireso@mail.nih.gov.

Name of Committee: National Institute on Drug Abuse Special Emphasis Panel Development of a Device to Objectively Measure Pain (R41/R42/R43/R44).

Date: March 29, 2018.

Time: 9:00 a.m. to 3:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852.

Contact Person: Julia Berzhanskaya, Ph.D., Scientific Review Officer, Office of Extramural Policy and Review, Division of Extramural Research, National Institute on Drug Abuse, NIH, DHHS, 6001 Executive Boulevard, Room 4234, MSC 9550, Bethesda, MD 20892, 301–827–5840, julia.berzhanskaya@nih.gov.

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Biomedical Imaging and Bioengineering; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.


Date: April 12, 2018.

Time: 8:00 a.m. to 7:00 p.m.

Agenda: To review and evaluate grant applications.

Place: Residence Inn Arlington Capital View, 2850 South Potomac Avenue, Arlington, VA 22202.

Contact Person: Dennis Hlasta, Ph.D., Scientific Review Officer, National Institute of Biomedical Imaging and Bioengineering National Institutes of Health, 6707 Democracy Blvd., Bethesda, MD 20892, (301) 451–4794, dennis.hlasta@nih.gov.

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

SUMMARY: The invention listed below is owned by an agency of the U.S. Government and is available for licensing to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.

FOR FURTHER INFORMATION CONTACT:

Jenish Patel, Ph.D., 240–669–2894; jenish.patel@nih.gov. Licensing information and copies of the U.S. patent application listed below may be obtained by communicating with the indicated licensing contact at the Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases, 5601 Fishers Lane, Rockville, MD 20852; tel. 301–496–2844. A signed Confidential Disclosure Agreement will be required to receive copies of unpublished patent applications.

SUPPLEMENTARY INFORMATION:

Technology description follows.

Protein Nanoparticles for Antigen Display in Vaccines

Description of Technology

The technology relates to a protein-based nanoparticle platform that allows presentation of immunogenic molecules such as influenza virus antigens. This protein platform is made up of hepatitis B capsid/core proteins. The core proteins contain immunogenic loop c/c1, where other antigens can be inserted and the chimeric protein retains the ability to form capsid-like particles. The technology describes the insertion of one or more copies of influenza epitopes derived from the globular head or the...
stem region of hemagglutinin protein into or around the c/e1 loop of the core protein. The nanoparticles formed by the use of Hepatitis B virus core proteins can be disassembled and re-assembled, allowing mixing of antigens. Furthermore, the nanoparticles can be expressed in prokaryotic and eukaryotic expression systems. Thus, the platform provides a means for an optimal display of influenza epitopes for the induction of immune response including broadly neutralizing antibodies against the virus and therefore has the potential to be further developed into an efficient universal vaccine against influenza virus infection.

This technology is available for licensing for commercial development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as well as for further development and evaluation under a research collaboration.

**Potential Commercial Applications**
- Vaccine against viruses; vaccines against influenza virus; universal influenza virus vaccine

**Competitive Advantages**
- The nanoparticles may be disassembled and re-assembled, allowing mixing of antigens
- Expression in prokaryotic and eukaryotic systems
- Avoids production and usage of live viruses for vaccine generation
- Effective immune response due to the use of authentic viral antigens
- Stability of particle and immunogenicity after high temperature exposure
- Incorporation of epitopes from group 1 and group 2 influenza viruses
- Broadly neutralizing antibodies against influenza virus

**Development Stage**
- Pre-clinical; in vivo data available (animal)
- **Inventors:** Audray K. Harris, Ph.D., (NIAID) and Dustin McCraw, Ph.D., (NIAID).
- **Licensing Contact:** Jenish Patel, Ph.D., 240–669–2894; jenish.patel@nih.gov.
- **Collaborative Research Opportunity:** The National Institute of Allergy and Infectious Diseases is also seeking statements of capability or interest from parties interested in collaborative research. NIAID would like a prospective collaborator to have one or more of the following capabilities: (1) Capacity to produce recombinant protein for animal vaccine studies; (2) perform and evaluate immunogenicity (antibody response) of influenza vaccine antigens in animal (e.g. mouse models); (3) perform and evaluate challenge and protection studies of vaccines and influenza viruses. (e.g. mouse models); and (4) if results are promising from animal studies, capacity to generate clinical grade materials and perform clinical studies. NIAID will consider executing a Confidentiality Agreement with a prospective collaborator to facilitate receipt of a Capability Statement if requested. For collaboration opportunities, please contact Jenish Patel, Ph.D., 240–669–2894; jenish.patel@nih.gov.

Dated: February 27, 2018.

Suzanne Frisbie,
Deputy Director, Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases.

[FR Doc. 2018–04701 Filed 3–8–18; 8:45 am]

**BILLING CODE 4140–01–P**

**DEPARTMENT OF HOMELAND SECURITY**

**U.S. Customs and Border Protection**

**Accreditation and Approval of SGS North America, Inc., as a Commercial Gauger and Laboratory**


**ACTION:** Notice of accreditation and approval of SGS North America, Inc., as a commercial gauger and laboratory.

**SUMMARY:** Notice is hereby given, pursuant to CBP regulations, that SGS North America, Inc., has been approved to gauge and accredited to test petroleum and petroleum products for customs purposes for the next three years as of August 24, 2017.

**DATES:** The accreditation and approval of SGS North America, Inc., as commercial gauger and laboratory became effective on August 24, 2017. The next triennial inspection date will be scheduled for August 2020.


**SUPPLEMENTARY INFORMATION:** Notice is hereby given pursuant to 19 CFR 151.12 and 19 CFR 151.13, that SGS North America, Inc., 12650 McManus Blvd., Suite 103, Newport News, VA 23602, has been approved to gauge and accredited to test petroleum and petroleum products for customs purposes, in accordance with the provisions of 19 CFR 151.12 and 19 CFR 151.13. SGS North America, Inc., is approved for the following gauging procedures for petroleum and certain petroleum products set forth by the American Petroleum Institute (API):

<table>
<thead>
<tr>
<th>API chapters</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Vocabulary.</td>
</tr>
<tr>
<td>3</td>
<td>Tank gauging.</td>
</tr>
<tr>
<td>7</td>
<td>Temperature Determination.</td>
</tr>
<tr>
<td>8</td>
<td>Sampling.</td>
</tr>
<tr>
<td>12</td>
<td>Calculations.</td>
</tr>
<tr>
<td>17</td>
<td>Maritime Measurements.</td>
</tr>
</tbody>
</table>

**SGS North America, Inc., is accredited for the following laboratory analysis procedures and methods for petroleum and certain petroleum products set forth by the U.S. Customs and Border Protection Laboratory Methods (CBPL) and American Society for Testing and Materials (ASTM):**

<table>
<thead>
<tr>
<th>CBPL No.</th>
<th>ASTM</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>27–54</td>
<td>ASTM D–1796</td>
<td>Standard test method for water and sediment in fuel oils by the centrifuge method (Laboratory procedure).</td>
</tr>
</tbody>
</table>